Cargando…

Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer: A network meta-analysis

BACKGROUND: Recently, many endocrine therapies have become available for hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer. Direct comparisons of these novel treatments to assess their added value, however, are lacking METHODS: Our aim w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Cho-Hao, Kang, Yi-No, Ho, Ching-Liang, Lin, Chin, Chen, Po-Huang, Wu, Yi-Ying, Huang, Tzu-Chuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2020
Materias:	5750
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220437/ https://www.ncbi.nlm.nih.gov/pubmed/32221087 http://dx.doi.org/10.1097/MD.0000000000019618

Ejemplares similares

Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis
por: Ma, Hong-Fang, et al.
Publicado: (2023)

Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: A case report
por: Dai, Jiali, et al.
Publicado: (2020)

The duration of endocrine therapy and breast cancer patients’ survival: A nationwide population-based cohort study
por: Chang, Chuan-Hsun, et al.
Publicado: (2019)

The curative effects of radiotherapy-based therapies for human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis
por: Shao, Minghai, et al.
Publicado: (2017)

Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis
por: Jiang, Mengjie, et al.
Publicado: (2021)

Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis
por: Zhang, Jingwen, et al.
Publicado: (2017)

Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment
por: Watanuki, Rurina, et al.
Publicado: (2020)

Positive estrogen receptor status is a poor prognostic factor in node-negative breast cancer: An observational study in Asian patients
por: Jung, Eun Jung, et al.
Publicado: (2021)

Expression of hormone receptors in low-grade adenosquamous carcinoma of the breast: A case report
por: Wu, Hai-Bo, et al.
Publicado: (2017)

Chemotherapy-induced prospective memory impairment in breast cancer patients with different hormone receptor expression
por: Li, Wen, et al.
Publicado: (2017)

Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer
por: Park, Sungmin, et al.
Publicado: (2017)

A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy
por: Ji, Dongmei, et al.
Publicado: (2020)

Impact of Breast Cancer Subtype Defined by Immunohistochemistry Hormone Receptor and HER2 Status on the Incidence of Immediate Postmastectomy Reconstruction
por: Wu, Wei, et al.
Publicado: (2016)

Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis
por: Liu, Xu, et al.
Publicado: (2017)

Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer
por: Choi, Jin Hyuk, et al.
Publicado: (2020)

Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report
por: Barchiesi, Giacomo, et al.
Publicado: (2019)

Efficacy of fulvestrant 500 mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure: A retrospective case series
por: Huang, Jian, et al.
Publicado: (2020)

Bacterial extracellular vesicles affect endocrine therapy in MCF7 cells
por: An, Jeongshin, et al.
Publicado: (2021)

Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer: A case report and narrative review
por: Ding, Jingxian, et al.
Publicado: (2020)

Estrogen Receptor Status Predicts Late-Onset Skeletal Recurrence in Breast Cancer Patients
por: Han, Hyun Ho, et al.
Publicado: (2016)

Association Between Insulin Resistance and Luminal B Subtype Breast Cancer in Postmenopausal Women
por: Nam, Sanggeun, et al.
Publicado: (2016)

A new strategy for the treatment of heavily pretreated metastatic breast cancer: A case report and review of the literature
por: Ge, Ting-Ting, et al.
Publicado: (2023)

Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors
por: Camacho, Fabian T., et al.
Publicado: (2017)

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Vitamin D Receptor Polymorphism and Breast Cancer Risk: A Meta-Analysis
por: Lu, Demin, et al.
Publicado: (2016)

Combination of Chinese medicinal formulas and chemotherapy for triple-negative breast cancer strengthens body resistance to eliminate pathogenic factors
por: Zhang, Yiyi, et al.
Publicado: (2022)

Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis
por: Lin, Yuxiang, et al.
Publicado: (2020)

Expression analysis of E-cad and vascular endothelial growth factor in triple-negative breast cancer patients of different ethnic groups in western China
por: Jiang, Weihua, et al.
Publicado: (2017)

Establishment of a risk scoring system for predicting locoregional recurrence in T1 to T2 node-negative breast cancer patients treated with mastectomy: Implications for postoperative radiotherapy
por: Li, Jin-luan, et al.
Publicado: (2017)

Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
por: Cao, Lu, et al.
Publicado: (2016)

Construction and validation of a transient receptor potential-related long noncoding RNA signature for prognosis prediction in breast cancer patients
por: Guo, Qiaonan, et al.
Publicado: (2023)

Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
por: Migliaccio, Ilenia, et al.
Publicado: (2015)

Prognostic value of IMP3 immunohistochemical expression in triple negative breast cancer
por: Sjekloča, Nikoleta, et al.
Publicado: (2020)

Application of the downgrade criteria to supplemental screening ultrasound for women with negative mammography but dense breasts
por: Kim, Soo-Yeon, et al.
Publicado: (2016)

MicroRNAs in the prognosis of triple-negative breast cancer: A systematic review and meta-analysis
por: Lü, Lingshuang, et al.
Publicado: (2017)

Development and validation of a risk stratification nomogram for predicting prognosis in bone metastatic breast cancer: A population-based study
por: Hou, Niuniu, et al.
Publicado: (2021)

Zolpidem-induced sneezing: A case report of positive rechallenge
por: Amraei, Razie, et al.
Publicado: (2018)

Association between miR-27a rs895819 polymorphism and breast cancer susceptibility: Evidence based on 6118 cases and 7042 controls
por: Liu, Yuan, et al.
Publicado: (2021)

Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database
por: Plasilova, Magdalena L., et al.
Publicado: (2016)

High expression of MORC2 predicts worse neoadjuvant chemotherapy efficacy in triple negative breast cancer
por: Liao, Xiaohong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_059ktd4r68mtssn8c7a0u0d12h